Table 4.
Multivariate linear regression for the association of DPP4 activity with thyroid function and TRAb in the GD group.
| Model 1 |
Model 2 |
Model 3 |
||||
|---|---|---|---|---|---|---|
| Variables | Standardized β (95% CI) | p | Standardized β (95% CI) | p | Standardized β (95% CI) | P |
| FT3 | 0.365 (0.172, 0.558) | <.001 | 0.356 (0.158, 0.554) | .001 | _ | _ |
| FT4 | 0.433 (0.247, 0.620) | <.001 | 0.421 (0.225, 0.617) | <.001 | _ | _ |
| TSH | −0.218 (−0.420, −0.016) | .035 | −0.195 (-14.841, −0.351) | .061 | _ | _ |
| TRAb | 0.433 (0.262, 0.632) | <.001 | 0.428 (0.239, 0.616) | <.001 | 0.325 (0.086, 0.564) | .008 |
Note: Model 1 unadjusted; Model 2 adjusted for age, sex and BMI; Model 3 adjusted for age, gender, BMI, FT3, lymphocyte count, AST and HOMA-IR. BMI: body mass index; FT3: free triiodothyronine; FT4: free thyroxine; TRAb: anti-thyrotropin receptor antibodies; AST: aspartate aminotransferase; HOMA-IR: homeostasis model assessment of insulin resistance; DPP-4: dipeptidyl peptidase-4; GD: Graves’ disease.